Tridek-One

About:

Tridek-One is a biopharmaceutical company aiming to develop immunomodulatory compounds targeting the CD31 pathway.

Website: https://tridekone.com/

Top Investors: Bpifrance, Advent Life Sciences, Pureos Bioventures, Bioqube Ventures, Kinled Holding

Description:

Tridek is a developer of immunomodulatory products intended for moderating overactive responses without blockade. The company's product is a peptide which maintains cluster of truncated CD31 to the membrane for a diversity of auto-immune and inflammatory disorders, enabling medical companies to treat their patients with better drugs and give them a better life.